HER2 Alterations in Non-Small Cell Lung Cancer - Episode 11

Unmet Needs in NSCLC Therapy

October 17, 2022

Solange Peters, MD, PhD, Timothy Craig Allen, MD, JD, FCAP, Ticiana A. Leal, MD, Mark A. Socinski, MD, Anil Vachani, MD, MS

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Biomarker Testing in NSCLC: Clinical Scenario

EP. 2: Approaches to Biomarker Testing in NSCLC

EP. 3: Liquid vs Solid Tumor Biopsies in NSCLC

EP. 4: HER2 Alterations in NSCLC: Clinical Scenario

EP. 5: The Role of HER2 Alterations in NSCLC

EP. 6: Testing Patients with NSCLC for HER2 Mutations

EP. 7: Current Treatment Options in NSCLC

EP. 8: Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

EP. 9: HER2-Targeted Therapies in NSCLC

EP. 10: Major Adverse Events of Anti-HER2 Therapies

Now Viewing

EP. 11: Unmet Needs in NSCLC Therapy

EP. 12: Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

EP. 13: Novel HER2-Targeted Therapies for NSCLC